ArticleTherapeutic advances in neurological disorders2022
Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Article in Therapeutic advances in neurological disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis: A Systematic Review and Meta-analysis.AJNR. American journal of neuroradiology · 2024Pooled it
- Contactin-associated protein-like 2 antibody-associated autoimmune encephalitis in children: case reports and systematic review of literature.Acta neurologica Belgica · 2023Pooled it
- Efficacy of immunotherapy and prognosis in anti-LGI1 encephalitis patients: A meta-analysis.Annals of clinical and translational neurology · 2023Pooled it
- Movement disorders in cell surface antibody mediated autoimmune encephalitis: a meta-analysis.Frontiers in neurology · 2023Pooled it
- Article
- Preliminary observations on the efficacy of efgartigimod in anti-LGI1-associated autoimmune encephalitis.Therapeutic advances in neurological disorders · 2026Article
- Relapse risk and functional outcomes in anti-LGI1 encephalitis: A multicenter retrospective analysis.Therapeutic advances in neurological disorders · 2026Article
- Differentiation between anti-CASPR2 encephalitis with initial psychiatric symptoms and primary psychiatric disorders, and a diagnostic prediction model: a prospective descriptive study.Journal of neurology · 2025Article
- Serum Autoantibody Titers and Neurofilament Light Chain Levels in CASPR2/LGI1 Encephalitis: A Longitudinal Study.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Cognitive and Patient-Reported Outcome Measures in LGI-1-IgG Autoimmune Encephalitis.Annals of clinical and translational neurology · 2025Article
- Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae.Journal of neurology, neurosurgery, and psychiatry · 2025Observational
- Article
- Neurodegeneration and the immune system: lessons from autoimmune encephalitis.Journal of neurology · 2025Review
- Anti-LGI1 encephalitis: clinical presentation, imaging features, and prognostic analysis.Frontiers in neurology · 2025Article
- Article
- Sleep Disturbances in Autoimmune Neurological Diseases: Mechanisms, Clinical Characteristics, Assessment, and Treatment Strategies.Current neurology and neuroscience reports · 2024Review
- Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Study on clinical features and factors related to long-term outcomes of antibody-negative autoimmune encephalitis.Annals of clinical and translational neurology · 2024Article
- Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.Journal of neurology · 2024Article
- Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the clinical characteristics of anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis and anti-contactin-associated protein-like 2 (Caspr2) encephalitis and to investigate factors associated with poor long-term neurological functional outcomes and relapse among patients in western China.
methodsIn this single-center prospective cohort study, we consecutively enrolled patients with anti-LGI1 encephalitis and anti-Caspr2 encephalitis from April 2014 to February 2021. Patient outcomes were assessed using the modified Rankin scale. Predictors of long-term functional outcomes and relapse were analyzed.
resultsForty-four anti-LGI1 encephalitis patients [median age: 44 years, range: 18-82 years; females: 25 (56.8%)], 35 anti-Caspr2 encephalitis patients [median age: 43 years, range: 14-80 years; females: 19 (54.3%)], and 5 dual-positive patients [median age: 44 years, range: 36-58 years; females: 5 (100%)] were enrolled. Overall, 86.4% anti-LGI1 encephalitis patients and 80% anti-Caspr2 encephalitis had a favorable neurological functional outcome (mRS 0-2). Tumor occurrence and weight loss were associated with poor long-term functional outcomes in anti-LGI1 encephalitis, whereas in anti-Caspr2 encephalitis, predictors included behavioral disorder at acute phase, abnormalities in brain magnetic resonance imaging, higher modified Rankin scale scores at onset, poor response to the initial immunotherapy at 4 weeks, age at onset<30 years, and relapse (
conclusionThe clinical characteristics such as age, gender, and tumor occurrence rates of anti-LGI1 encephalitis and anti-Caspr2 encephalitis in western China are different from those in the Western countries. Most patients in our study had favorable long-term functional outcomes. The relapse rates are still high in both types of encephalitis, which warrants caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.